Thore Buergel

Thore Buergel

Auto-generated profile, based on publicly available information

Thore Buergel

Synthetic Biology Group, Institute for Pharmacy and Molecular Biotechnology and Center for Quantitative Analysis of Molecular and Cellular Biosystems, University of Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TBThore Buergel
Thore Buergel
JSJakob Steinfeldt
Jakob Steinfeldt
GRGreg Ruyoga
Greg Ruyoga
MPMaik Pietzner
Maik Pietzner
DBDaniele Bizzarri
Daniele Bizzarri
ULUlf Landmesser
Ulf Landmesser
Risk stratification is critical for the early identification of high-risk individuals and disease prevention. Here we explored the potential of nuclear magnetic resonance (NMR) spectroscopy-derived metabolomic profiles to inform on multidisease risk beyond conventional clinical predictors for the onset of 24 common conditions, including metabolic, vascular, respiratory, musculoskeletal and neurological diseases and cancers. Specifically, we trained a neural network to learn disease-specific metabolomic states from 168 circulating metabolic markers measured in 117,981 participants with ~1.4 million person-years of follow-up from the UK Biobank and validated the model in four independent cohorts. We found metabolomic states to be associated with incident event rates in all the investigated conditions, except breast cancer. For 10-year outcome prediction for 15 endpoints, with and without established metabolic contribution, a combination of age and sex and the metabolomic state equaled or outperformed established predictors. Moreover, metabolomic state added predictive information over comprehensive clinical variables for eight common diseases, including type 2 diabetes, dementia and heart failure. Decision curve analyses showed that predictive improvements translated into clinical utility for a wide range of potential decision thresholds. Taken together, our study demonstrates both the potential and limitations of NMR-derived metabolomic profiles as a multidisease assay to inform on the risk of many common diseases simultaneously.

1 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAmir Bahmani
Amir Bahmani
AAArash Alavi
Arash Alavi
TBThore Buergel
Thore Buergel
SUSushil Upadhyayula
Sushil Upadhyayula
QWQiwen Wang
Qiwen Wang
MSMichael P Snyder
Michael P Snyder
The large amount of biomedical data derived from wearable sensors, electronic health records, and molecular profiling (e.g., genomics data) is rapidly transforming our healthcare systems. The increasing scale and scope of biomedical data not only is generating enormous opportunities for improving health outcomes but also raises new challenges ranging from data acquisition and storage to data analysis and utilization. To meet these challenges, we developed the Personal Health Dashboard (PHD), which utilizes state-of-the-art security and scalability technologies to provide an end-to-end solution for big biomedical data analytics. The PHD platform is an open-source software framework that can be easily configured and deployed to any big data health project to store, organize, and process complex biomedical data sets, support real-time data analysis at both the individual level and the cohort level, and ensure participant privacy at every step. In addition to presenting the system, we illustrate the use of the PHD framework for large-scale applications in emerging multi-omics disease studies, such as collecting and visualization of diverse data types (wearable, clinical, omics) at a personal level, investigation of insulin resistance, and an infrastructure for the detection of presymptomatic COVID-19.

13 May 2019 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
JBJulius Upmeier zu Belzen
Julius Upmeier zu Belzen
TBThore Bürgel
Thore Bürgel
SHStefan Holderbach
Stefan Holderbach
FBFelix Bubeck
Felix Bubeck
LALukas Adam
Lukas Adam
RERoland Eils
Roland Eils

15 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JSJakob Steinfeldt
Jakob Steinfeldt
BWBenjamin Wild
Benjamin Wild
TBThore Manuel Buergel
Thore Manuel Buergel
MPMaik Pietzner
Maik Pietzner
JBJulius Valten Upmeier zu Belzen
Julius Valten Upmeier zu Belzen
RERoland Eils
Roland Eils
The COVID-19 pandemic exposed, with few exceptions, a global deficiency in delivering systematic, data-driven guidance to protect citizens and coordinate vaccination programs. At the same time, medical histories are routinely recorded in most healthcare systems and are instantly available for risk assessment. Here, we demonstrate the utility of medical history in determining the risk for 1,883 diseases across clinical specialties and facilitating the rapid response to emerging health threats at the example of COVID-19. We developed a neural network to learn disease-specific risk states from routinely collected health records of 502,460 UK Biobank participants, demonstrating risk stratification for nearly all conditions, and validated this model on 229,830 individuals from the All of US cohort. When integrated into Cox Proportional Hazard Models, we observed significant discriminative improvements over basic demographic predictors for 1,774 (94.3%). After transferring the unmodified risk models to the All of US cohort, the discriminate improvements were replicated for 1,347 (89.8%) of 1,500 investigated endpoints, demonstrating model generalizability across healthcare systems and historically underrepresented groups. We then show that these risk states can be used to identify individuals vulnerable to severe COVID-19 and mortality. Our study demonstrates the currently underused potential of medical history to rapidly respond to emerging health threats by systematically estimating risk for thousands of diseases at once at minimal cost.

16 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
TBThore Buergel
Thore Buergel
LLLukas Loock
Lukas Loock
JSJakob Steinfeldt
Jakob Steinfeldt
LHLaura Hoffmann
Laura Hoffmann
SKSteffen E Emil Künzel
Steffen E Emil Künzel
RERoland Eils
Roland Eils
Early detection of high-risk individuals is crucial for healthcare systems to cope with changing demographics and an ever-increasing patient population. Images of the retinal fundus are a non-invasive, low-cost examination routinely collected and potentially scalable beyond ophthalmology. Prior work demonstrated the potential of retinal images for risk assessment for common cardiometabolic diseases, but it remains unclear whether this potential extends to a broader range of human diseases. Here, we extended a retinal foundation model (RETFound) to systematically explore the predictive potential of retinal images as a low-cost screening strategy for disease onset across >750 incident diseases in >60,000 individuals. For more than a third (n=308) of the diseases, we demonstrated improved discriminative performance compared to readily available patient characteristics. This included 281 diseases outside of ophthalmology, such as type 2 diabetes (Delta C-Index: UK Biobank +0.073 (0.068, 0.079)) or chronic obstructive pulmonary disease (Delta C-Index: UK Biobank +0.047 (0.039, 0.054)), showcasing the potential of retinal images to complement screening strategies more widely. Moreover, we externally validated these findings in 7,248 individuals from the EPIC-Norfolk Eye Study. Notably, retinal information did not improve the prediction for the onset of cardiovascular diseases compared to established primary prevention scores, demonstrating the need for rigorous benchmarking and disease-agnostic efforts to design cost-efficient screening strategies to improve population health. We demonstrated that predictive improvements were attributable to retinal vascularisation patterns and less obvious features, such as eye colour or lens morphology, by extracting image attributions from risk models and performing genome-wide association studies, respectively. Genetic findings further highlighted commonalities between eye-derived risk estimates and complex disorders, including novel loci, such as IMAP1 , for iron homeostasis. In conclusion, we present the first comprehensive evaluation of predictive information derived from retinal fundus photographs, illustrating the potential and limitations of easily accessible and low-cost retinal images for risk assessment across common and rare diseases. Research in context: Evidence before this study: Before undertaking this study, we reviewed the literature on the predictive utility of medical imaging for disease onset, focusing particularly on retinal fundus photographs. We conducted searches in databases including PubMed and Google Scholar, spanning from the inception of these databases to January 1, 2023. Our search terms included “retinal fundus photography”, “disease prediction”, “machine learning”, “deep learning”, and “healthcare AI”, without language restrictions. Prior research has shown the promise of retinal images in diagnosing and predicting a range of conditions, notably within ophthalmology and specific systemic diseases such as diabetes and cardiovascular diseases. However, a comprehensive evaluation of retinal images’ predictive potential across a broad spectrum of diseases, particularly those without known associations to retinal changes, was lacking. Studies identified varied in quality, with many focusing on single diseases or small datasets, indicating a potential risk of bias and overfitting. Added value of this study: Our study extends the application of retinal fundus photographs from ophthalmological and systemic diseases to more than 750 incident diseases, leveraging a foundation model combined with a deep multi-task neural network. This represents the first systematic exploration of the predictive potential of retinal images across the human phenome, significantly expanding the scope of diseases for which these images could serve as a low-cost screening strategy. Moreover, we rigorously compare the predictive value of retinal images against established primary prevention scores for cardiovascular diseases, showing both the strengths and limitations of this approach. This dual focus provides a nuanced understanding of where retinal imaging can complement existing screening strategies and where it may not offer additional predictive value. Implications of all the available evidence: The evidence from our study, combined with existing research, suggests that retinal fundus photographs hold promise for predicting disease onset across a wide range of conditions, far beyond their current use. However, our work also emphasizes the importance of contextualizing these findings within the broader landscape of available prediction tools and established primary prevention. The implications for practice include the potential integration of retinal imaging into broader screening programs, particularly for diseases where predictive gains over existing methods are demonstrated. For policy, our findings advocate for further investment in AI and machine learning research in healthcare, particularly in methods that improve upon or complement existing prediction models. Future research should focus on refining these predictive models, exploring the integration of retinal imaging with other biomarkers, and conducting prospective studies to validate the clinical utility of these approaches in diverse populations.

30 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JBJulius Upmeier zu Belzen
Julius Upmeier zu Belzen
LALucas Arnoldt
Lucas Arnoldt
NHNoah Hollmann
Noah Hollmann
LHLuis Hermann
Luis Hermann
KNKhue M. Nguyen
Khue M. Nguyen
RERoland Eils
Roland Eils
Genetic prediction of complex phenotypes typically relies on additive linear models, which scale well but cannot capture non-additive effects or deeply integrate molecular and clinical data. Domain-specific neural networks have driven advances in images, text, and other modalities, but genome-scale neural networks remain challenging because genotypes are sparse and high-dimensional, effective sample sizes are limited, and generic architectures lack interpretability. Here, we introduce the omnigenic neural network, a biologically structured architecture inspired by the omnigenic model of complex traits. The model learns hierarchical representations of biological processes, accommodates multimodal inputs, supports transfer learning, and enables multitask prediction. Models trained in the UK Biobank and evaluated in the All of Us cohort for ischemic heart disease, type 2 diabetes, and schizophrenia outperformed published PGS Catalog and PRS-CSx scores. A multitask model trained across 36 cardiovascular endpoints further outperformed corresponding single-phenotype models and baselines. The architecture provides systems-level interpretability by quantifying the contributions of biological processes, which were consistent with established disease mechanisms. It also captures non-linear interactions between variants. Analysis of these interactions using Integrated Hessians revealed patterns concordant with previously reported epistatic associations. Together, these findings establish the omnigenic neural network as a flexible framework for interpretable, multimodal, and multitask genomic prediction.